Publication
A case of success: complete response to Radium-223 in metastatic castration-resistant prostate cancer
dc.contributor.author | Soares De Pinho, Inês | |
dc.contributor.author | Esperança Martins, Miguel | |
dc.contributor.author | Machado, Bárbara | |
dc.contributor.author | Dâmaso, Sara | |
dc.contributor.author | Brás, Raquel | |
dc.contributor.author | Cantinho, Guilhermina | |
dc.contributor.author | Fernandes, Isabel | |
dc.contributor.author | Costa, Luis | |
dc.date.accessioned | 2024-11-19T15:38:50Z | |
dc.date.available | 2024-11-19T15:38:50Z | |
dc.date.issued | 2024 | |
dc.description | © Copyright 2024 Soares de Pinho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited | pt_PT |
dc.description.abstract | Radium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, and there is no universal consensus about how it should be monitored. Furthermore, a scintigraphy flare phenomenon may lead to false-positive tracer uptake in responsive cases, thereby misleading the interpretation of imaging results. We present the case of a 67-year-old male with mCRPC and exclusive bone disease treated with Ra223. The bone scintigraphy after the end of the treatment showed an apparent aggravation of the lesions, corresponding to a flare phenomenon, with an almost complete resolution after three months. The patient maintained a scintigraphic response for seven months. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Cureus. 2024 Feb 5;16(2):e53637 | pt_PT |
dc.identifier.doi | 10.7759/cureus.53637 | pt_PT |
dc.identifier.eissn | 2168-8184 | |
dc.identifier.uri | http://hdl.handle.net/10400.5/95443 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Springer Nature | pt_PT |
dc.relation.publisherversion | https://www.cureus.com/ | pt_PT |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
dc.subject | Bone disease | pt_PT |
dc.subject | Flare | pt_PT |
dc.subject | Prostate cancer | pt_PT |
dc.subject | Radium-223 | pt_PT |
dc.subject | Response | pt_PT |
dc.title | A case of success: complete response to Radium-223 in metastatic castration-resistant prostate cancer | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.title | Cureus | pt_PT |
person.familyName | Soares de Pinho | |
person.familyName | Esperança Martins | |
person.familyName | Lopes Brás | |
person.familyName | Cantinho | |
person.familyName | Costa | |
person.givenName | Inês | |
person.givenName | Miguel | |
person.givenName | Raquel | |
person.givenName | Guilhermina | |
person.givenName | Luis | |
person.identifier | 1201606 | |
person.identifier.ciencia-id | 7B10-E6A8-C67E | |
person.identifier.ciencia-id | 041E-4ADE-FB64 | |
person.identifier.orcid | 0000-0002-8377-0179 | |
person.identifier.orcid | 0000-0002-6858-7341 | |
person.identifier.orcid | 0000-0001-5150-9235 | |
person.identifier.orcid | 0000-0002-1096-2241 | |
person.identifier.orcid | 0000-0002-4782-7318 | |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |
relation.isAuthorOfPublication | 175aa033-b64e-4a94-b8c8-8bed65034181 | |
relation.isAuthorOfPublication | e73cbe66-c79a-4f6b-9bed-b3af464000db | |
relation.isAuthorOfPublication | 305603cb-e914-45ea-a3d0-c4f9ef7bbbe0 | |
relation.isAuthorOfPublication | c727fa0f-151e-43d7-b2a6-6468a5be6cfe | |
relation.isAuthorOfPublication | 8a2ab4c6-ba86-4433-b4b7-6256d81890e5 | |
relation.isAuthorOfPublication.latestForDiscovery | c727fa0f-151e-43d7-b2a6-6468a5be6cfe |